Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients

Journal of Clinical Virology

Volumn 57, Issue 2, 2013, Pages 103-108

  Coffin, C S ^a,b   Osiowy, C ^c   Myers, R P ^a   Gill, M J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Chronic hepatitis B; HBV genotype; HBV variants; Human immunodeficiency virus; Nucleoside analog; Quantitative hepatitis B surface antigen

Indexed keywords

EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENOTYPE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MUTATION; NORTH AMERICA; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS LOAD; AGED; BLOOD; CLASSIFICATION; COHORT ANALYSIS; COINFECTION; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876953407     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.02.004     Document Type: Article

References (75)

1. Thio C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49:S138-S145.
2. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:S6-S9.
3. Hall H.I., Geduld J., Boulos D., Rhodes P., An Q., Mastro T.D., et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr 2009, 51(Suppl. 1):S13-S20.
4. Mallet V., Vallet-Pichard A., Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int 2011, 31(Suppl. 1):135-139.
5. Thio C., Seaberg E., Skolasky R.J., Phair J., Visscher B., Munoz A., et al. Multicenter AIDS cohort study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter cohort study (MACS). Lancet 2002, 360:1921-1926.
6. Nikolopoulos G.K., Paraskevis D., Hatzitheodorou E., Moschidis Z., Sypsa V., Zavitsanos X., et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009, 48:1763-1771.
7. Puoti M., Airoldi M., Bruno R., Zanini B., Spinetti A., Pezzoli C., et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002, 4:27-35.
8. Colin J.F., Cazals-Hatem D., Loriot M.A., Martinot-Peignoux M., Pham B.N., Auperin A., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999, 29:1306-1310.
9. Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
10. Peters M.G. Managing hepatitis B coinfection in HIV-infected patients. Curr HIV/AIDS Rep 2005, 2:122-126.
11. Klein M.B., Baril J.G., Charron M.A., Fortin C., Lalonde R., Matte M.F., et al. Management and treatment of hepatitis B virus in patients with HIV infection: a practical guide for health care professionals. Can J Infect Dis Med Microbiol 2011, 22:88-96.
12. Soriano V., Vispo E., Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS 2011, 25:1013-1014.
13. Puoti M., Cozzi-Lepri A., Paraninfo G., Arici C., Moller N.F., Lundgren J.D., et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006, 11:567-574.
14. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004, 24(Suppl. 1):3-10.
15. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005, 25(Suppl. 1):9-19.
16. Teo C.G., Locarnini S.A. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther 2010, 15:445-449.
17. Sheldon J., Ramos B., Garcia-Samaniego J., Rios P., Bartholomeusz A., Romero M., et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007, 46:279-282.
18. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005, 10:727-734.
19. Norder H., Courouce A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47:289-309.
20. Ramos B., Nunez M., Martin-Carbonero L., Sheldon J., Rios P., Labarga P., et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007, 44:557-561.
21. Buster E.H., Hansen B.E., Lau G.K., Piratvisuth T., Zeuzem S., Steyerberg E.W., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002-2009.
22. Sanchez-Tapias J.M., Costa J., Mas A., Bruguera M., Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002, 123:1848-1856.
23. Kao J.H., Chen P.J., Lai M.Y., Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554-559.
24. Chu C.J., Hussain M., Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002, 122:1756-1762.
25. Yu M.W., Yeh S.H., Chen P.J., Liaw Y.F., Lin C.L., Liu C.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005, 97:265-272.
26. Kato H., Orito E., Gish R.G., Bzowej N., Newsom M., Sugauchi F., et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002, 35:922-929.
27. Osiowy C., Gordon D., Borlang J., Giles E., Villeneuve J.P. Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol 2008, 89:3009-3015.
28. Jaroszewicz J., Calle Serrano B., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522.
29. Sonneveld M.J., Zoutendijk R., Janssen H.L., Hepatitis B. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011, 18:449-457.
30. Chan H.L., Thompson A., Martinot-Peignoux M., Piratvisuth T., Cornberg M., Brunetto M.R., et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011, 55:1121-1131.
31. Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.
32. Thibault V., Stitou H., Desire N., Valantin M.A., Tubiana R., Katlama C. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther 2011, 16:199-205.
33. Maylin S., Boyd A., Lavocat F., Gozlan J., Lascoux-Combe C., Miailhes P., et al. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012, 26:939-949.
34. Jaroszewicz J., Reiberger T., Meyer-Olson D., Mauss S., Vogel M., Ingiliz P., et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS ONE 2012, 7:e43143.
35. Zoutendijk R., Zaaijer H.L., de Vries-Sluijs T.E., Reijnders J.G., Mulder J.W., Kroon F.P., et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis 2012, 206:974-980.
36. Soriano V., Puoti M., Peters M., Benhamou Y., Sulkowski M., Zoulim F., et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008, 22:1399-1410.
37. Rockstroh J.K., Bhagani S., Benhamou Y., Bruno R., Mauss S., Peters L., et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
38. Thio C.L. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther 2010, 15:487-491.
39. Matthews G.V., Bartholomeusz A., Locarnini S., Ayres A., Sasaduesz J., Seaberg E., et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20:863-870.
40. de Vries-Sluijs T.E., Reijnders J.G., Hansen B.E., Zaaijer H.L., Prins J.M., Pas S.D., et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010, 139:1934-1941.
41. Lada O., Gervais A., Branger M., Peytavin G., Roquebert B., Collin G., et al. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver Int 2012, 32:93-101.
42. Amini-Bavil-Olyaee S., Herbers U., Sheldon J., Luedde T., Trautwein C., Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009, 49:1158-1165.
43. Schirmer P., Winters M., Holodniy M. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. J Clin Virol 2011, 52:261-264.
44. Woodward C.L., Hall A.M., Williams I.G., Madge S., Copas A., Nair D., et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009, 10:482-487.
45. Krentz H.B., Gill M.J. Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta. Canada Health Policy 2011, 103:124-129.
46. Heathcote E.J. Demography and presentation of chronic hepatitis B virus infection. Am J Med 2008, 121:S3-S11.
47. Krentz H.B., Kliewer G., Gill M.J. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005, 6:99-106.
48. Osiowy C., Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J Clin Microbiol 2003, 41:5473-5477.
49. Stuyver L., Van Geyt C., De Gendt S., Van Reybroeck G., Zoulim F., Leroux-Roels G., et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707.
50. Osiowy C., Kaita K., Solar K., Mendoza K. Molecular characterization of hepatitis B virus and a 9-year clinical profile in a patient infected with genotype I. J Med Virol 2010, 82:942-948.
51. Hoffmann C.J., Seaberg E.C., Young S., Witt M.D., D'Acunto K., Phair J., et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009, 23:1881-1889.
52. Spradling P.R., Richardson J.T., Buchacz K., Moorman A.C., Brooks J.T. Prevalence of chronic hepatitis B virus infection among patients in the HIV outpatient study, 1996-2007. J Viral Hepat 2010, 17:879-886.
53. Konopnicki D., Mocroft A., de Wit S., Antunes F., Ledergerber B., Katlama C., et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593-601.
54. Krentz H.B., Gill J. Monitoring and adjusting for future needs in response to changing HIV policies. Lancet Infect Dis 2010, 10:671-672.
55. Kosi L., Reiberger T., Payer B.A., Grabmeier-Pfistershammer K., Strassl R., Rieger A., et al. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir+emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat 2012, 19:801-810.
56. Thio C.L., Smeaton L., Saulynas M., Hwang H., Saravanan S., Kulkarni S., et al. Characterization of HIV-HBV co-infection in a multi-national HIV-infected cohort. AIDS 2012.
57. Ratcliffe L., Beadsworth M.B., Pennell A., Phillips M., Vilar F.J. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011, 25:1051-1056.
58. Mikulska M., Taramasso L., Giacobbe D.R., Caligiuri P., Bruzzone B., Di Biagio A., et al. Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. J Med Virol 2012, 84:1340-1343.
59. Locarnini S.A. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998, 27:294-297.
60. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
61. Brau N., Fox R.K., Xiao P., Marks K., Naqvi Z., Taylor L.E., et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007, 47:527-537.
62. Chang J.J., Sirivichayakul S., Avihingsanon A., Thompson A.J., Revill P., Iser D., et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol 2009, 83:7649-7658.
63. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998, 102:968-975.
64. Simon B., Kundi M., Puchhammer E. Analysis of mutations in the S gene of HBV strains of patients with chronic infection by online bioinformatics tools. J Clin Microbiol 2012.
65. Pollicino T., Amaddeo G., Restuccia A., Raffa G., Alibrandi A., Cutroneo G., et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 2012, 56:434-443.
66. Fujisaki S., Yokomaku Y., Shiino T., Koibuchi T., Hattori J., Ibe S., et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 2011, 49:1017-1024.
67. Pourkarim M.R., Lemey P., Amini-Bavil-Olyaee S., Houspie L., Verbeeck J., Rahman M., et al. Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: overt and occult infection. J Med Virol 2011, 83:1876-1884.
68. Dao D.Y., Balko J., Attar N., Neak E., Yuan H.J., Lee W.M., et al. Hepatitis B virus genotype G: prevalence and impact in patients co-infected with human immunodeficiency virus. J Med Virol 2011, 83:1551-1558.
69. Silva A.C., Spina A.M., Lemos M.F., Oba I.T., Guastini Cde F., Gomes-Gouvea M.S., et al. Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil. Mem Inst Oswaldo Cruz 2010, 105:770-778.
70. Mata Marin J.A., Arroyo Anduiza C.I., Calderon G.M., Cazares Rodriguez S., Fuentes Allen J.L., Arias Flores R., et al. Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico. Ann Hepatol 2012, 11:47-51.
71. Lacombe K., Massari V., Girard P.M., Serfaty L., Gozlan J., Pialoux G., et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006, 20:419-427.
72. Chen B.F., Liu C.J., Jow G.M., Chen P.J., Kao J.H., Chen D.S. Evolution of hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. J Gen Virol 2006, 87:39-49.
73. Huang Y., Lok A.S. Viral factors and outcomes of chronic HBV infection. Am J Gastroenterol 2011, 106:93-95.
74. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
75. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526.